Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.
Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.
J Clin Anesth. 2021 Aug;71:110223. doi: 10.1016/j.jclinane.2021.110223. Epub 2021 Mar 3.
Intraoperative systemic lidocaine has become widely accepted as an adjunct to general anesthesia, associated with opioid-sparing and enhanced recovery. We hypothesized that perioperative systemic lidocaine improves postoperative pain and enhances the quality of recovery (QoR) in patients following video-assisted thoracic surgery (VATS).
Prospective, single-center, double-blind, randomized placebo-controlled clinical trial.
Single institution, tertiary university hospital.
Adult patients aged 18 to 65 undergoing VATS were eligible for participation.
Patients enrolled in this study were randomized to receive either system lidocaine (a bolus of 1.5 mg kg, followed by an infusion of 2 mg kg h until the end of the surgical procedure) or identical volumes and rates of 0.9% saline.
The primary outcome was a global QoR-15 score 24 h after surgery. Secondary outcomes included postoperative pain score, cumulative opioid consumption, emergence time, length of PACU stay, adverse events, and patient satisfaction.
There was no difference in the global QoR-15 scores at 24 h postoperatively between the lidocaine and saline groups (median 117, IQR 113.5-124, vs. median 116, IQR 111-120, P = 0.067), with a median difference of 3 (95% CI 0 to 6, P = 0.507). Similarly, postoperative pain scores, postoperative cumulative opioid consumption, PACU length of stay, the occurrence of PONV, and patient satisfaction were comparable between the two groups (all P > 0.05).
Our current findings do not support using perioperative systemic lidocaine as a potential strategy to improve postoperative pain and enhance QoR in patients undergoing VATS.
Chinese Clinical Trial Registry (identifier: ChiCTR1900027515).
术中全身应用利多卡因已被广泛接受为全身麻醉的辅助手段,与减少阿片类药物使用和促进康复有关。我们假设围手术期全身应用利多卡因可改善电视辅助胸腔镜手术(VATS)后患者的术后疼痛,并提高康复质量(QoR)。
前瞻性、单中心、双盲、随机安慰剂对照临床试验。
单一机构、三级大学医院。
18 至 65 岁接受 VATS 的成年患者有资格参加。
参加本研究的患者被随机分配接受全身利多卡因(负荷量 1.5mg/kg,随后以 2mg/kg/h 的速度输注,直至手术结束)或相同容量和速度的 0.9%生理盐水。
主要结果是术后 24 小时的总体 QoR-15 评分。次要结果包括术后疼痛评分、累积阿片类药物用量、苏醒时间、PACU 停留时间、不良事件和患者满意度。
利多卡因组和生理盐水组术后 24 小时的总体 QoR-15 评分无差异(中位数 117,IQR 113.5-124,vs. 中位数 116,IQR 111-120,P=0.067),中位数差异为 3(95%CI 0 至 6,P=0.507)。同样,两组术后疼痛评分、术后累积阿片类药物用量、PACU 停留时间、PONV 发生率和患者满意度无差异(均 P>0.05)。
我们目前的研究结果不支持将围手术期全身应用利多卡因作为一种潜在策略,用于改善 VATS 患者的术后疼痛和提高 QoR。
中国临床试验注册中心(注册号:ChiCTR1900027515)。